Page last updated: 2024-09-04

vatalanib and pd 153035

vatalanib has been researched along with pd 153035 in 2 studies

Compound Research Comparison

Studies
(vatalanib)
Trials
(vatalanib)
Recent Studies (post-2010)
(vatalanib)
Studies
(pd 153035)
Trials
(pd 153035)
Recent Studies (post-2010) (pd 153035)
2764298232261

Protein Interaction Comparison

ProteinTaxonomyvatalanib (IC50)pd 153035 (IC50)
Cyclin-G-associated kinaseHomo sapiens (human)0.26
Mitogen-activated protein kinase 13Homo sapiens (human)6.3
Dihydrofolate reductaseHomo sapiens (human)0.2
Dihydrofolate reductaseMus musculus (house mouse)0.2
Tyrosine-protein kinase ABL1Homo sapiens (human)0.03
Tyrosine-protein kinase transforming protein AblAbelson murine leukemia virus0.4787
Epidermal growth factor receptorHomo sapiens (human)0.1416
Protein kinase C alpha typeBos taurus (cattle)0.4787
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)2.735
Cyclin-dependent kinase 1Homo sapiens (human)0.4787
Fructose-1,6-bisphosphatase 1Homo sapiens (human)1
Platelet-derived growth factor receptor betaHomo sapiens (human)0.2
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.709
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.4787
Dihydrofolate reductasePneumocystis carinii0.2
Potassium-transporting ATPase subunit betaSus scrofa (pig)0.03
Potassium-transporting ATPase alpha chain 1Sus scrofa (pig)0.03
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.8445
Mitogen-activated protein kinase 12Homo sapiens (human)6.3
Mitogen-activated protein kinase 11Homo sapiens (human)6.3
Mitogen-activated protein kinase 14Homo sapiens (human)6.3
Dihydrofolate reductaseRattus norvegicus (Norway rat)0.2
MAP kinase-interacting serine/threonine-protein kinase 1Homo sapiens (human)0.63
Histamine H3 receptorRattus norvegicus (Norway rat)1
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2.025

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheung, K; Dushin, RG; Floyd, MB; Fraser, HL; Ingalls, CL; Loganzo, F; Nittoli, T; Ravi, MR; Tan, X; Wissner, A1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1

Other Studies

2 other study(ies) available for vatalanib and pd 153035

ArticleYear
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Bioorganic & medicinal chemistry, 2007, Jun-01, Volume: 15, Issue:11

    Topics: Adenosine Triphosphate; Binding Sites; Biological Assay; Cells, Cultured; ErbB Receptors; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2

2007
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
chemdatabank.com